DeepMed Research

THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Intrathecal Hydromorphone for Labor Analgesia

Not Applicable

Terminated

Conditions: Pregnancy

Interventions: Drug: Hyperbaric bupivacaine
Drug: Hydromorphone
Drug: Fentanyl

First Posted Date: 2014-10-29

Last Posted Date: 2022-03-18

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 21

Registration Number: NCT02277782

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Intervention With Vitamin D and Omega-3 Supplements and Incident Heart Failure

Phase 3

Completed

Conditions: Heart Failure

Interventions: Drug: Vitamin D and fish oil
Dietary Supplement: Fish oil (EPA/DHA) alone
Other: Placebo
Drug: Vitamin D alone

First Posted Date: 2014-10-22

Last Posted Date: 2022-03-18

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 25871

Registration Number: NCT02271230

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Salt and TH-17 in Healthy Human Subjects

Not Applicable

Terminated

Conditions: Th17 Helper Immune Cells
Autoimmunity
Salt Intake
Sodium Chloride

Interventions: Dietary Supplement: Low salt diet
Dietary Supplement: Low salt diet + IV normal saline
Dietary Supplement: Liberal salt diet

First Posted Date: 2014-10-10

Last Posted Date: 2021-06-08

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 9

Registration Number: NCT02261688

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Treat-to-target in RA: Collaboration To Improve adOption and adhereNce

Not Applicable

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Behavioral: Learning Collaborative

First Posted Date: 2014-10-09

Last Posted Date: 2024-08-09

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 11

Registration Number: NCT02260778

Promoting Respect and Ongoing Safety Through Patient-centeredness, Engagement, Communication and Technology

Not Applicable

Completed

Conditions: Medical Intensive Care Unit (MICU) Patients
Oncology Unit Patients

Interventions: Other: Web-Based Patient Centered Toolkit (PCTK)
Behavioral: The Patient-SatisfActive® Model

First Posted Date: 2014-10-07

Last Posted Date: 2022-03-14

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 4368

Registration Number: NCT02258594

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study

Phase 4

Terminated

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Ambrisentan plus Spironolactone
Drug: Ambrisentan plus Placebo

First Posted Date: 2014-10-01

Last Posted Date: 2019-11-15

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 2

Registration Number: NCT02253394

Locations: 🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States

Mail Outreach To Increase Vaccination Acceptance Through Engagement

Not Applicable

Completed

Conditions: Influenza, Human
Human Flu
Influenza

Interventions: Behavioral: Core letter signed by the Director of the National Vaccine Program
Behavioral: Core letter signed by SG + enhanced implementation prompt
Behavioral: Core letter signed by Surgeon General
Behavioral: Core letter signed by Surgeon General + implementation prompt

First Posted Date: 2014-09-18

Last Posted Date: 2017-07-12

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 228000

Registration Number: NCT02243774

Locations: 🇺🇸
Centers for Medicare & Medicaid Services, Baltimore, Maryland, United States

VITamin D and OmegA-3 TriaL: Effects on Mammographic Density and Breast Tissue

Not Applicable

Conditions: Benign Breast Disease

Interventions: Dietary Supplement: Vitamin D and fish oil placebo
Dietary Supplement: Vitamin D placebo and fish oil placebo
Dietary Supplement: Fish oil and vitamin D placebo
Dietary Supplement: Vitamin D and fish oil

First Posted Date: 2014-09-15

Last Posted Date: 2022-04-07

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 3894

Registration Number: NCT02239874

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Trial of Feedback on Blood Use

Not Applicable

Terminated

Conditions: Compliance With Restrictive RBC Transfusion Guideline

Interventions: Behavioral: Feedback

First Posted Date: 2014-09-05

Last Posted Date: 2020-05-18

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 426

Registration Number: NCT02232568

Locations: 🇺🇸
Richard Kaufman MD, Boston, Massachusetts, United States
🇺🇸
Temple University, Philadelphia, Pennsylvania, United States
🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States

and more 2 locations

Safety and Cardiovascular Efficacy of Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD

Phase 4

Completed

Conditions: Chronic Hemodialysis (ESRD)

Interventions: Drug: Hydralazine/Isorsorbide Dinitrate
Drug: Placebo

First Posted Date: 2014-08-29

Last Posted Date: 2021-04-27

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 17

Registration Number: NCT02228408

Locations: 🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy